Drug Reaction with Eosinophilia and Systemic Symptoms Induced by Diosmin and Hesperidin: A Case Report

References

• Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol. 2013;68(5):693.e691; quiz 706–698. doi:10.1016/j.jaad.2013.01.033
   Web of Science ®Google Scholar
• Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–1080. doi:10.1111/bjd.12501
   PubMed Web of Science ®Google Scholar
• Martínez JD, Franco R, Sáenz LM, et al. DRESS and Stevens-Johnson syndrome overlap secondary to allopurinol in a 50-year-old man-a diagnostic and treatment challenge: case Report. Life. 2023;13(12):2551 doi:10.3390/life13122251.
   Google Scholar
• Huwait E, Mobashir M. Potential and therapeutic roles of diosmin in human diseases. Biomedicines. 2022;10(5):1076. doi:10.3390/biomedicines10051076
   PubMed Web of Science ®Google Scholar
• Pyrzynska K. Hesperidin: a review on extraction methods, stability and biological activities. Nutrients. 2022;14(12):2387. doi:10.3390/nu14122387
   PubMed Web of Science ®Google Scholar
• Gerges SH, Wahdan SA, Elsherbiny DA et al. Pharmacology of diosmin, a citrus flavone glycoside: an updated review. Eur J Drug Metab Pharmacokinet. 2022;47(1):1–18. doi:10.1007/s13318-021-00731-y
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs. 2003;63(1):71–100. doi:10.2165/00003495-200363010-00005
   PubMed Web of Science ®Google Scholar
• Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37(2):143–154. doi:10.23736/S0392-9590.18.03975-5
   PubMed Web of Science ®Google Scholar
• Nicolaides AN. From symptoms to leg edema: efficacy of Daflon 500 mg. Angiology. 2003;54(Suppl 1):S33–44. doi:10.1177/0003319703054001S05
   PubMedGoogle Scholar
• Sheikh P, Lohsiriwat V, Shelygin Y. Micronized purified flavonoid fraction in hemorrhoid disease: a systematic review and meta-analysis. Adv Ther. 2020;37(6):2792–2812. doi:10.1007/s12325-020-01353-7
   PubMed Web of Science ®Google Scholar
• Attia TM. Efficacy and safety of daflon® in the treatment of idiopathic epistaxis. Am J Rhinol Allergy. 2019;33(1):62–68. doi:10.1177/1945892418809237
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.154
   PubMed Web of Science ®Google Scholar
• Pandit S, Soni D, Krishnamurthy B, Belhekar MN. Comparison of WHO-UMC and naranjo scales for causality assessment of reported adverse drug reactions. J Patient Saf. 2024. doi:10.1097/PTS.0000000000001213
   PubMedGoogle Scholar
• Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996;15(4):250–257. doi:10.1016/S1085-5629(96)80038-1
   PubMed Web of Science ®Google Scholar
• Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. ScientificWorldJournal. 2013;2013:162750. doi:10.1155/2013/162750
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Iyyam Pillai S, Subramanian SP. Synthesis, spectral characterization, and biochemical evaluation of antidiabetic properties of a new zinc-diosmin complex studied in high fat diet fed-low dose streptozotocin induced experimental type 2 diabetes in rats. Biochem Res Int. 2015;2015:350829. doi:10.1155/2015/350829
   PubMedGoogle Scholar
• Meyer OC. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology. 1994;45(6 Pt 2):579–584. doi:10.1177/000331979404500614
   PubMed Web of Science ®Google Scholar
• Marappa U, Mishra D, Shamshavali K, et al. A rare case of diosmin and hesperidin induced chest tightness and dyspnoea; 2017. Available from: https://www.researchgate.net/publication/328134208_A_Rare_Case_of_Diosmin_and_Hesperidin_Induced_Chest_Tightness_and_Dyspnea. Accessed January 25, 2024.
   Google Scholar
• Söylemez H, Kiliç S, Atar M et al. Effects of micronised purified flavonoid fraction on pain, semen analysis and scrotal color Doppler parameters in patients with painful varicocele; results of a randomized placebo-controlled study. Int Urol Nephrol. 2012;44(2):401–408. doi:10.1007/s11255-011-0038-3
   PubMed Web of Science ®Google Scholar
• Roztocil K, Stvrtinová V, Strejcek J. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int Angiol. 2003;22(1):24–31.
   PubMed Web of Science ®Google Scholar
• Cazaubon M, Benigni JP, Steinbruch M et al. Is there a difference in the clinical efficacy of diosmin and micronized purified flavonoid fraction for the treatment of chronic venous disorders? Review of available evidence Vasc Health Risk Manag. 2021;17:591–600. doi:10.2147/VHRM.S324112
   PubMed Web of Science ®Google Scholar
• Steinbruch M, Nunes C, Gama R, et al. Is nonmicronized diosmin 600 mg as effective as micronized diosmin 900 mg plus hesperidin 100 mg on chronic venous disease symptoms? Results of a noninferiority study. Int J Vasc Med. 2020;2020:4237204. doi:10.1155/2020/4237204
   PubMed Web of Science ®Google Scholar
• Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;73(5):843–848. doi:10.1016/j.jaad.2015.07.017
   PubMed Web of Science ®Google Scholar
• Bergmann MM, Caubet JC. Role of in vivo and in vitro tests in the diagnosis of Severe Cutaneous Adverse Reactions (SCAR) to drug. Curr Pharm Des. 2019;25(36):3872–3880. doi:10.2174/1381612825666191107104126
   PubMed Web of Science ®Google Scholar
• Porebski G, Piotrowicz-Wojcik K, Spiewak R. ELISpot assay as a diagnostic tool in drug hypersensitivity reactions. J Immunol Methods. 2021;495:113062. doi:10.1016/j.jim.2021.113062
   PubMed Web of Science ®Google Scholar